remains normal (84) . Therefore, age-dependent falls in GFR and glomerular injury can occur in the absence of glomerular hypertension. Nevertheless, the sclerosis-prone Sprague-Dawley (SD) rat shows an early rise in glomerular blood pressure as well as age-dependent systemic hypertension (30, 83) , which exacerbates the rate of injury development.
Structural changes in aging man include thickening of the glomerular basement membrane (GBM), expansion of the glomerular mesangium, and extracellular matrix leading to glomerular sclerosis. Additional changes include glomerular ischemia and arteriolar, atherosclerosis, and tubulointerstitial injury, all leading to loss of functioning nephrons (45, 51, 59, 70) . In aging humans, this loss of function and structural injury occurs so slowly that it usually has no obvious impact. However, the loss of "renal reserve" renders the aged kidney susceptible to failure when other insults are superimposed. In some rat strains, CKD is a major cause of death, presumably reflecting co-morbidities such as hypertension that result from genetic background (96) . There are also genetic quantitative trait loci that enhance susceptibility to renal failure by various mechanisms (101) .
Thus the severity and rate of development of agedependant CKD is highly variable and determined by a complex interplay between resistance/susceptibility genes and the diet/environment. There is also a marked sex difference in rate of deterioration of the aging kidney, with females being protected. The remainder of this review will consider some aspects of this sexual dimorphism.
Sexual Dimorphism of the Kidney
Cross-sectional clinical studies show that age-related falls in GFR are delayed in women, and when they do occur they proceed relatively slowly (7, 105) . In the rat, female sex almost always confers protection from 142 1548-9213/08 8.00 ©2008 Int. Union Physiol. Sci./Am. Physiol. Soc.
Many studies report an age-dependent fall in the glomerular filtration rate (GFR) during aging in man (105) and rats (6) . How much this reflects "normal aging" and how much is due to undiagnosed cardiovascular and renal disease is unclear. A fall in GFR is not inevitable in man since ~30% of "normal" subjects in longitudinal studies show preserved renal function over many years (52) , and GFR can remain stable even in the very old (27) . This suggests that co-morbidities such as hypertension, atherosclerosis, glucose intolerance/diabetes, obesity, dyslipidemias, and chronic kidney disease (CKD) contribute importantly to the rate of agedependant kidney deterioration (8, 37, 45, 111) .
In addition, genetic background is a major determinant. African Americans show a more rapid rate of "kidney aging" compared with Caucasians (110) . However, it is difficult to dissociate socioeconomic disparities from race/genetics in humans, since diet and environment also have a major impact. The rate of decline in GFR with age varies between laboratory rat strains housed under similar environmental conditions, reinforcing a role for genetic background, whereas high caloric and/or protein intake also exacerbates the rate of age-dependent decline in GFR (6) .
Although variable, falls in GFR with advancing age are due to both functional and structural changes. The functional decline is secondary to falls in renal plasma flow (RPF) due to renal vasoconstriction and occurs even in normotensive humans and rats and is exacerbated in hypertensives subjects (3, 28, 51, 90) . In the normotensive Munich Wistar (MW) rat, GFR falls slowly due to parallel increases in afferent and efferent renal arteriolar resistances, which maintain normal glomerular blood pressure. Thus, in MWs, the structural damage precedes increased glomerular blood pressure (3), although even in this strain glomerular blood pressure eventually increases (1) . Male rats of the MWF/ZTM strain exhibit accelerated kidney disease with aging, yet glomerular blood pressure age-dependent declines in GFR, irrespective of strain (6) , although GFR is lower in the young adult female vs. the male due to a higher renal vascular resistance (3, 65) .
The preservation of GFR in the female has been linked to a delayed fall in renal plasma flow. For example, in the meta-analysis by Wesson (105) , the effective renal plasma flow (ERPF) begins to fall later in women than in men. This difference is particularly prominent in a recent clinical study on potential renal transplant donors (7) with ERPF falling by more than 10% per decade in normal men between ages 20 and 50 and by ~1% per decade in women over the same ages. By age 70, however, the values of ERPF (factored for surface area) were similar in a small group of normotensive men and women (46) . The falls in ERPF are due to renal vasoconstriction. It should be noted that care must be used when ERPF is calculated from PAH clearance since renal extraction of PAH is reportedly lower in women than in men (17). However, we observed a lower RPF in the women vs. men using inulin clearance factored by extraction (65) and glomerular plasma flow calculated from single nephron filtration fraction and SNGFR (3) .
In the aging male MW rat, both afferent and efferent renal arteriolar resistances increase in parallel, whereas these resistances tend to decline with age in the initially vasoconstricted female kidney (and in this strain, in both sexes, the glomerular blood pressure remains constant with age). There are no other studies on sexual dimorphism in glomerular blood pressure in aging. As a surrogate measure, the filtration fraction tends to increase slightly from ~16 to 22% in normal men (perhaps suggesting a mild increase in glomerular blood pressure), while remaining stable at ~20% in women between ages 20 and 60 (7) .
In terms of structural damage, the findings in humans are equivocal, with McLachlan et al. (59) reporting a greater vulnerability of men to glomerular sclerosis, whereas Neugarten et al. (70) reported no sex difference. In rats, however, there is a clear sex difference with females of most strains exhibiting substantial protection (3, 6, 24) (FIGURE 1).
Role and Actions of Estrogen
It is likely that the sexual dimorphism in kidney aging, with females protected, is associated with the beneficial vascular actions of the estrogens. Indeed, the rate of progression of renal disease in women is slower than in men (68) . Female C57Bl6 mice become susceptible to age-related glomerulosclerosis after menopause (115) , and estrogen supplementation reverses glomerular sclerosis in male TGF-␤ overexpressing mice (9) and female sclerosis-prone ROP Os/+ mice (23).
The vascular actions of estrogen are complicated, however, as indicated by the recent unfavorable clinical trials on hormone replacement therapy (HRT) in postmenopausal women (40, 87) . The type of HRT employed is critical since, although native 17␤-estradiol is likely to be beneficial, the complex conjugated equine estrogens (containing many estrogens, progestins, androgens, and "other substances"), used in WHI and HERS, have less predictable actions (20). Age of initiation of HRT is also critical, and older women showed less benefit and/or increased cardiovascular risk compared with women in whom HRT was initiated at or close to menopause (20). This could reflect impact of aging and/or loss of endogenous estrogen on estrogen receptor (ER) distribution and hence estrogen responsiveness (86) .
There are two major ER subtypes, ␣ and ␤, and the data on renal and vascular distribution of the subtypes is sparse and controversial. Rogers and colleagues report that ER␣ predominates in female SD rat kidney cortex, whereas ER␤ predominates in the male (86) . In contrast, Lu et al. (56) report the opposite with sham nephrectomized male SDs showing greater ER␣ abundance vs. females. The renal ER␣ distribution is inversely related to 17␤-estradiol level in normal male and female rats (86) and in the Dahl R rat where renal cortical ER␣ falls with ovariectomy (26), although ovariectomy increases ER␤ in both Dahl S and R. However, the impact of 17␤-estradiol level on the ERs is location specific, and ER expression is under complex control (61) . Aging has variable impact on ER distribution, with slight declines in both subtypes in the vasculature of old female SHRs (107), whereas ER␣ mRNA and protein increases in the kidney of the old female mouse, with decreases in the male (93) . Of course, posttranslational changes can also modify receptor activity independent of mRNA and protein abundance, but there is little information on impact of aging.
The relative role of these ER subtypes in renal and cardiovascular pathology is unclear, although ER␣ activation may be injurious in some situations. Studies by Lane and colleagues using ER knockout mice (ERKOs) suggest that ER␣ may be injurious by mediating the compensatory hypertrophy after uninephrectomy and with diabetes since the ␣ERKO is protected from glomerular enlargement and matrix accumulation (55, 99) . Maric and colleagues reported increased renal ER␣ in Type 1 diabetic female rats together with a fall in plasma estradiol (104) . In contrast, ER␣ is required for vascular repair from atherosclerosis in mice of both sexes (61) , and ER␣ depletion in Dahl S rats on high salt is associated with worsening hypertension and renal damage (26). ER␣ increases in old female (protected) mouse kidneys (93) , and mesangial cells from GS prone mice express decreased ER␣ and ER␤ (77) . In addition, ␣ERKO female (but not male) mice develop albuminuria and glomerular damage with age (22). In experimentally induced CKD (5/6 nephrectomy), greater falls occur in ER␣ in male (susceptible to injury) than females, although the final protective actions of estrogens (both ER dependent and independent) include suppression of glomerular mesangial cell growth and inhibition of mesangial extracellular matrix accumulation; key events in the development of glomerular sclerosis (19, 21, 34, 49, 67, 71, 95, 108, 115) . Loss of these protective actions after menopause contributes to the decline in renal function and development of structural damage in aging women.
Although usually beneficial, estrogen is not universally good for the kidney. There are ER-independent actions of estrogen on kidney that increase the prosclerotic IGF in the db/db D2 mouse kidney and overwhelm any protective actions of ER stimulation (44) . Estradiol promotes renal injury and stroke in the stroke-prone SHR (98) and increases renal damage with both chronic NOS inhibition and ANGII infusion in female rats (75) . Also, the progression of CKD is faster in the female analbuminemic rat and the Zucker obese rat (32, 42) in association with more severe hypertriglyceridemia.
Role and Actions of Androgen
Much of the health benefit of female sex is due to the presence of estrogens, but there are some situations in which low androgen levels may be protective. The aging male MW rat develops slowly evolving renal vasoconstriction and glomerular sclerosis (3) . Both the intact and ovariectomized females are protected, and castration of the young male prevents agedependent injury (FIGURE 2), suggesting a primary damaging influence of the male gonadal hormone milieu. There is no sex difference in glomerular blood pressure in this strain with aging, and although glomerular volume is greater in the intact male vs. intact female, glomerular volumes are similar between intact (vulnerable) and castrated (protected) males. This suggests that androgens do not promote kidney damage via hemodynamic mechanisms (3) .
There are many non-hemodynamic mechanisms of glomerular injury, some of which target the glomerular mesangium. The androgens stimulate mesangial extracellular matrix (ECM) production and cause excessive mesangial expansion and higher levels of glomerular procollagen mRNA levels after subtotal nephrectomy (54) . Also, glomerular metalloprotease activity increases with age in intact females but not in males, and castration of the male restores glomerular metalloprotease activity as well as protecting against glomerular injury (80) . Elliot et al. reported that, although ovariectomy protects the ␣ERKO mouse from glomerular sclerosis, testosterone supplementation promotes glomerular sclerosis (22). Studies by Reckelhoff and colleagues in the SHR show that androgen receptor antagonism lowers BP in the male, whereas testosterone administration to the female raises BP (79) .
In contrast, in men, higher androgens correlate with lower BP, arterial wall thickness, and CAD (53 (56) , so the significance of ER␣ abundance in this model is unclear. In some settings, ER␤ may be protective since the ␤ERKO develops age-dependent hypertension (116) and ␤ERKO females develop greater cardiac injury following ischemia/reperfusion (31).
The ERs are nuclear receptors, form homo-and heterodimers, and can activate transcription by interaction with estrogen response elements in target genes and also by direct interactions with transcription factors (61) . Of note, after uterus and pituitary, the kidney has the greatest number of estrogen-regulated genes. The ER␣ seems to be primarily responsible since estrogen-dependent renal gene regulation is intact in ovariectomized ␤ERKO mice given 17␤-estradiol but suppressed in the ␣ERKO (41) . There are also nongenomic, rapid actions of estrogen on membrane-bound ERs (both ␣ and ␤) (61), although their role in kidney has not yet been defined. Some of the actions of estrogen are independent of estrogen receptors and are mediated by the methoxyestradiol metabolites of estradiol (19, 108) . The actions of estrogen are therefore complex and sometimes unpredictable. Reno-REVIEWS FIGURE 1. GFR, percent glomerular sclerosis, and 24-h urine total protein excretion GFR (from inulin clearances), % glomerular sclerosis, and 24-h urine total protein excretion (UproteinV) in 18-to 20-mo-old intact males and females and castrated males and ovariectomized females of the Munich Wistar rat strain. GFR data is expressed as a % of the young adult (4 mo old) value for each group. Rats were ovariectomized/castrated at 8 wk of age. androgen levels are associated with increased cardiovascular risk and insulin resistance, whereas testosterone supplementation improves insulin sensitivity (44) . Testosterone supplementation is anti-atherogenic, and, although associated with a mild reduction in HDL cholesterol, the larger fall in LDL cholesterol may be beneficial in net terms (88) . Indeed, several clinical studies conclude that, in men, testosterone has overall beneficial cardiovascular actions and that some of this benefit is mediated by "non-traditional," rapid actions of testosterone (78) . The gradual decline in testosterone levels that occurs with aging may contribute to age-dependent renal dysfunction.
In women, the impact of androgen level on cardiovascular health is controversial. Women with polycystic ovary syndrome (PCOS) have elevated androgen levels and are also at increased cardiovascular risk (53) , suggesting that increased androgen may be damaging in women. However, cardiovascular risk is also associated with insulin resistance (94) and when insulin sensitivity is normal in women with PCOS, endothelial function is also normal, despite increased androgens (13) . Administration of low-dose testosterone to postmenopausal women (12) and hypo-pituitary premenopausal women does not increase cardiovascular risk over 1-2 years and may improve insulin sensitivity (62) . Even high-dose testosterone given to female-tomale transsexuals has no adverse effect on BP or insulin resistance, although HDL cholesterol falls (33). A recent review article concludes that there is no clear link between elevated testosterone levels and cardiovascular disease in women and that the increased cardiovascular disease in PCOS is more related to insulin resistance and hypoadiponectinemia (85) . Interestingly, a low testosterone-to-bioavailable estrogen ratio correlates with a pro-atherogenic adipocytokine profile with high leptin and low adiponectin (50) , also a feature of the metabolic syndrome.
The androgens work by many mechanisms, one of which requires conversion to estrogen by aromatization. Castration of male LDL-receptor-deficient mice worsens the atherosclerosis, and although testosterone and estrogen supplementation are both protective, the testosterone protection is abrogated by aromatase inhibition (66) . Similar findings have been reported in "in vitro" studies in endothelium (64) . It is also clear that estrogens exert protective actions on the male cardiovascular system and that falls in testosterone-derived estrogen may contribute to the age-dependent atherogenesis seen in aging men (18).
In summary, estrogen is usually protective of peripheral endothelium and kidney across species. Although androgens often cause cardiovascular risk and exacerbate kidney damage in rats, in clinical studies, higher androgen levels seem to associate with better cardiovascular health in men; the association is still controversial in women. We have a lot to learn about sex steroids and cardiovascular and kidney aging. Clearly, simply looking at estrogen or androgen levels is not adequate. We need measures of the androgen-to-estrogen ratio, the activity of the aromatase enzymes, and AR and ER distribution, as well as a better understanding of the receptor and nonreceptor-mediated genomic and rapid actions of the sex steroids. Also, castration studies in animals do more than remove estrogen or androgens; thus the impact on the entire hormonal milieu must be considered.
Sex Steroids, Aging, and the Nitric Oxide System
Androgens and estrogens interact with many systems that impact on cardiovascular and renal function and structure. This article concludes with some consideration of interactions with nitric oxide (NO) that have major influences on cardiovascular health.
NO is made throughout the body and acts locally. NO from vascular endothelium produces vasodilation and has anti-growth effects that include inhibition of mesangial and vascular smooth muscle cell growth and extracellular matrix production (4, 5, 47) . Therefore, chronic NO deficiency causes vasoconstriction with increased BP, unrestrained vascular smooth muscle and mesangial cell growth, extracellular matrix overproduction, and consequent fibrosis. Chronic NO deficiency occurs in many types of CKD and contributes to progressive loss of function and evolving structural damage (4, 5). As discussed below, NO deficiency also develops during normal aging.
Total body NO production can be estimated from the urinary excretion of NO X (NO X = NO 2 note, however, that the male rat is more vulnerable to hypertension and proteinuria produced by low-dose NOS inhibition, an effect largely attributed to adverse actions of the androgens (103) . In addition, male rats are more susceptible to both fructose feeding and hypercholesterolemic-induced vascular and renal injury, both injuries secondary to NO deficiency (2, 102) . Given the greater susceptibility of the male to NO deficiency-induced CKD, it is likely that the NO deficiency of aging plays a role in the sex difference in agedependent kidney damage.
Possible Mechanisms of AgeDependent Falls in NO Production
A fall in U NOX V reflects a reduction in total body NO production but does not define the location(s). Much of the reduced U NOX V reflects a reduction in endothelial NO activity with age with associated endothelial dysfunction, seen in humans and rats (10, 16, 58) . Oral arginine supplementation reverses endothelial dysfunction in healthy aged humans (10), suggesting substrate deficiency and/or an increased competitive inhibitor with aging. In addition, decreased abundance or activity of the NOS enzymes, due to reduction in protein content, reduced availability of essential co-factors, or high oxidant state can also cause decreased NO production (4, 5) .
Substrate Availability
Circulating L-arginine levels are well maintained in normal aging humans (46) and in the male rat (63), although after a 12-h fast plasma L-arginine concentration falls in the aging male SD rat (82) , suggesting that food deprivation stress may induce substrate deficiency in the aged. In the unstressed male rat, the renal cortical and brain cerebellar levels of L-arginine were unchanged by age, whereas expression of the genes involved in renal arginine synthesis and small intestinal citrulline synthesis were either unchanged or upregulated in both male and female SD rats (63) .
Circulating NOS Inhibitors
Increases in NOS inhibitors, such as asymmetric dimethylarginine (ADMA), have been reported in the aging male rat (57, 109) . Plasma ADMA levels also rise in humans in healthy old age, in both men and women, correlating with declines in renal plasma flow (46) . Although there is no sex difference in plasma ADMA at 69 and 25 yr of age (46) , the increase is delayed in women (91) . There are probably multiple mechanisms of increased plasma ADMA with age. Renal clearance falls with age (see above), but this is a minor route of ADMA removal in humans (~15%), whereas almost no intact ADMA is excreted in the urine in the rat (72, 73) NO X intake is controlled. Total NO production (from UNOXV) falls in the aging male SD rat as age-dependent CKD develops, whereas, in the female, UNOXV remains unchanged with age, and kidney damage is delayed (FIGURE 2) (24, 38, 82, 97) . The U NOX V also correlates inversely with the kidney damage in the aging male Fischer 344; when maintained on a normal protein diet, U NOX V falls and kidney damage develops, but dietary protein restriction is associated with preserved U NOX V and structure (97) . In humans on normal sodium intake, U NOX V falls with age (58, 89) , although this age difference is lost on either low or high sodium intake. The fall in U NOX V correlates with developing endothelial dysfunction (58) , and although there is no clinical data available on sex differences in U NOX V with aging, the appearance of endothelial dysfunction is delayed in aging women vs. men (15) . There is also sexual dimorphism in the NO system in young adults, with premenopausal women making more total NO than men (29) and a greater abundance of the constitutive NO synthases (NOS) in young adult female vs. male rat kidney (69, 81) .
The sex differences in NO are due, in part, to estrogen, which has multiple potent actions to stimulate NO production from both eNOS and the neuronal NOS isoform that is predominant in the kidney epithelium. Estrogen stimulates NO directly at both genomic and nongenomic levels, indirectly by reduction of endogenous inhibitors, and the antioxidant actions of estrogens may prolong the active life of NO (39, 76) . Studies using ERKO mice and selective agonists and antagonists suggest that ER␣ provides the primary stimulus to eNOS-derived NO (35).
Androgens have variable actions on NO production with testosterone-induced inhibition of NO-dependent vasodilation being reported in some parts of the circulation and stimulation in others (76) . Both vascular smooth muscle and endothelial cells express the AR (53) , and AR stimulation can increase endothelial NO production (114) . Men express plasma membrane ER␣ and ER␤ receptors on vascular endothelium and vascular smooth muscle cells, which contribute to NO-dependent vasodilation (18). In addition, the adrenal androgen dehydroepiandrosterone (DHEA) stimulates endothelial NO by rapid, non-AR and non-ER mechanisms (106) .
The literature on estrogen and androgen effects of NO is incomplete and contradictory, which makes definitive conclusions impossible. It is interesting to ADMA removal is by metabolism by dimethylarginine dimethylamino-hydrolase (DDAH), and the kidney has the highest levels of DDAH of any organ. It is possible that DDAH activity falls with age, contributing to ADMA accumulation. This would certainly explain the delayed rise in women since estrogen stimulates DDAH activity (39) . Synthesis of ADMA might also increase with aging since protein methyltransferase 1 (PRMT1), which methylates arginine, is activated by oxidative stress (11) .
NOS Protein Activity/Abundance
The abundance of endothelial eNOS declines with age and oxidative stress increases, which will both impair endothelial NO production and cause endothelial dysfunction (112) . In addition to declines in systemic endothelial NO production, renal NOS generation falls as age-dependent kidney damage develops. As shown in FIGURE 3, decreased renal cortical abundance of the neuronal NOS (nNOS) occurs in the aging male SD (24). Renal eNOS abundance also falls late, but the fall in renal cortical nNOS begins in middle age, precedes injury, and declines further as the kidney damage increases in severity, in the old rat. Renal cortical nNOS abundance also falls in other models of CKD and may contribute to progression (5) . Of note, the female rat, which is protected from the age-dependent kidney damage, shows preserved nNOS protein levels (FIGURE 3). Estrogen also stimulates nNOS at the gene level and may inhibit iNOS expression, although this is controversial (14, 26, 36, 60, 74, 76, 113) . However, we find no difference in either eNOS or nNOS protein abundance in renal cortex between young male and female rats (24) as also reported for eNOS by Neugarten et al. (69) , although increased medullary eNOS and eNOS in whole kidney homogenates have been observed in female vs. male SD (69, 81) .
In summary, the total NO production falls with age in the male rat and in humans (no sex difference data available). Given the stimulatory actions of the estrogens on NO production, at least regional NO production is likely to be greater in premenopausal women than in men and decline after menopause. The impact of androgens on NO production is variable and unclear at present but may be net protective in men. The age-dependent fall in total NO production is not due to substrate limitation but increases in circulating antagonists likely contribute. The abundance of the renal nNOS also likely contributes to the age-dependent CKD, contributing to the greater susceptibility of the male kidney to age-dependent damage.
In conclusion, although age-dependent kidney injury and declines in function are not inevitable, they will occur to some extent in most individuals. There is a pronounced sexual dimorphism with females protected probably due to the protective estrogens and perhaps the lower concentrations of potentially damaging androgens, although this is controversial. There is clear evidence of decreased total NO production and endothelial dysfunction in aging humans, and renal NOS activity and abundance falls in the aging male rat coincident with evolving injury. In contrast, there is no systemic or renal NOS deficiency in the aging female rat. Although substrate (arginine) production is preserved, there are increases in the circulating NOS inhibitor ADMA that would promote generalized declines in NO production. In the kidney, both major constitutive isoforms (eNOS and nNOS) are reduced, with declines in nNOS occurring early. In addition, the increased oxidative stress of aging leads to NO inactivation, and formation of advanced glycosylated end products prevent NO from reaching its targets (100). Thus there are multiple pathways leading to regional and widespread NO deficiency in aging.
The endothelial dysfunction promotes general cardiovascular disease and likely hastens progression of kidney damage. The loss of the renal nNOS may also play a role in the progression of the age-dependent kidney damage. progression in women with non-diabetic renal disease (92) . The possibility that some of the cardiovascular actions of androgens are mediated via estrogen is intriguing and warrants further study.
